Difference between revisions of "Team:AFCM-Egypt"
Ahmedashry (Talk | contribs) |
Aymanshafei (Talk | contribs) |
||
| (118 intermediate revisions by 3 users not shown) | |||
| Line 2: | Line 2: | ||
{{Template:AFCM-Egypt/main}} | {{Template:AFCM-Egypt/main}} | ||
{{Template:AFCM-Egypt/owl.carousel}} | {{Template:AFCM-Egypt/owl.carousel}} | ||
| + | {{Template:AFCM-Egypt/header}} | ||
<html> | <html> | ||
<head> | <head> | ||
| Line 9: | Line 10: | ||
<meta name="author" content="Web Domus Italia"> | <meta name="author" content="Web Domus Italia"> | ||
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"> | <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"> | ||
| − | <meta name="viewport" content="width=device-width, initial-scale=1.0" | + | <meta name="viewport" content="width=device-width, initial-scale=1.0"> |
| − | + | ||
<style> | <style> | ||
| − | + | .HOME a {border: 1px solid #fff; | |
| − | . | + | background: rgba(255,255,255, 0.3) !important} |
| − | + | ||
| − | + | .fa-arrow-up:before { | |
| − | + | content: "\f062"; | |
} | } | ||
| − | + | .fa-arrow-right:before { | |
| − | + | content: "\f061"; | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
} | } | ||
| − | + | .active { | |
| − | + | border: 1px solid #fff; | |
| − | + | background: rgba(255,255,255, 0.3) !important; | |
| + | } | ||
| + | #myBtn { | ||
| + | display: none; | ||
| + | position: fixed; | ||
| + | bottom: 50px; | ||
| + | right: 10px; | ||
| + | z-index: 99; | ||
| + | border: none; | ||
| + | outline: none; | ||
| + | background-color: transparent; | ||
| + | color: #ffffff; | ||
| + | cursor: pointer; | ||
| + | padding: 5px 10px 5px 10px; | ||
| + | border-radius: 10px; | ||
} | } | ||
| + | #myBtn:hover{ | ||
| + | color:#777; | ||
| + | } | ||
| + | .buttons { | ||
| + | display: table; | ||
| + | height: 100%; | ||
| + | width: 100%; | ||
| + | } | ||
| + | p a { | ||
| + | background: rgba(255, 255, 255, 0); | ||
| + | border-bottom: 1px solid; | ||
| + | color: #fff; | ||
| + | line-height: 1.4; | ||
| + | padding: .25em; | ||
| + | text-decoration: none; | ||
| + | } | ||
| + | |||
| + | p a:hover { | ||
| + | background: white; | ||
| + | color: #E1332D; | ||
| + | } | ||
| + | |||
| + | .btn-5 { | ||
| + | border: 0 solid; | ||
| + | box-shadow: inset 0 0 20px rgba(255, 255, 255, 0); | ||
| + | outline: 1px solid; | ||
| + | outline-color: rgba(255, 255, 255, 0.5); | ||
| + | outline-offset: 0px; | ||
| + | text-shadow: none; | ||
| + | -webkit-transition: all 1250ms cubic-bezier(0.19, 1, 0.22, 1); | ||
| + | transition: all 1250ms cubic-bezier(0.19, 1, 0.22, 1); | ||
| + | } | ||
| + | |||
| + | .btn-5:hover { | ||
| + | border: 1px solid; | ||
| + | box-shadow: inset 0 0 20px rgba(255, 255, 255, 0.5), 0 0 20px rgba(255, 255, 255, 0.2); | ||
| + | outline-color: rgba(255, 255, 255, 0); | ||
| + | outline-offset: 15px; | ||
| + | text-shadow: 1px 1px 2px #427388; | ||
| + | } | ||
| + | |||
| + | .dots { | ||
| + | height: 13px; | ||
| + | width: 13px; | ||
| + | display: inline-block; | ||
| + | padding: 5px; | ||
| + | background-color: gray; | ||
| + | border-radius: 50px; | ||
| + | cursor: pointer; | ||
| + | } | ||
| + | |||
| + | .adots { | ||
| + | background-color: #f70404; | ||
| + | } | ||
.btn { | .btn { | ||
| − | + | margin-right: 4px; | |
| − | + | margin-bottom: 4px; | |
| − | + | font-family: "Raleway", Arial, sans-serif; | |
| − | font-size: | + | font-size: 16px; |
font-weight: 400; | font-weight: 400; | ||
| − | + | -webkit-border-radius: 30px; | |
| − | + | -moz-border-radius: 30px; | |
| − | + | -ms-border-radius: 30px; | |
| − | + | border-radius: 30px; | |
| − | + | -webkit-transition: 0.5s; | |
| − | + | -o-transition: 0.5s; | |
| − | + | transition: 0.5s; | |
} | } | ||
| − | + | .btn-primary { | |
| − | + | background: #4a148c !important; | |
| − | + | color: #fff; | |
| − | + | border:none | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
} | } | ||
| − | + | .btn-primary:hover { | |
| − | + | background: #4a148c !important; | |
| − | + | color: #fff; | |
| − | + | border:none | |
| − | + | ||
| − | + | ||
| − | + | ||
} | } | ||
| − | .btn | + | .btn-outline { |
| − | + | background: rgba(255, 255, 255, .15) !important; | |
| + | font-size: 16px; | ||
| + | -webkit-transition: 0.3s; | ||
| + | -o-transition: 0.3s; | ||
| + | transition: 0.3s; | ||
} | } | ||
| − | .btn- | + | .btn-outline:hover, .btn-outline:focus, .btn-outline:active { |
| − | + | box-shadow: none; | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | .btn- | + | |
| − | + | ||
| − | box-shadow: | + | |
| − | + | ||
| − | + | ||
| − | + | ||
} | } | ||
| − | + | .btn.with-arrow { | |
| − | + | position: relative; | |
| − | + | -webkit-transition: 0.3s; | |
| − | + | -o-transition: 0.3s; | |
| − | + | transition: 0.3s; | |
| − | + | } | |
| − | + | .btn.with-arrow i { | |
| − | + | visibility: hidden; | |
| − | + | opacity: 0; | |
| − | + | position: absolute; | |
| − | + | right: 0px; | |
| − | + | top: 50%; | |
| + | margin-top: -8px; | ||
| + | -webkit-transition: 0.2s; | ||
| + | -o-transition: 0.2s; | ||
| + | transition: 0.2s; | ||
| + | } | ||
| + | .btn.with-arrow:hover { | ||
| + | padding-right: 50px; | ||
| + | } | ||
| + | .btn.with-arrow:hover i { | ||
| + | color: #fff; | ||
| + | right: 18px; | ||
| + | visibility: visible; | ||
| + | opacity: 1; | ||
| + | } | ||
</style> | </style> | ||
| + | </head> | ||
<body> | <body> | ||
| − | |||
| − | < | + | <div class="twitter-feed purple" style="padding-bottom:250px"> |
| − | <div class="container" | + | <div class="container section-wrapper" style="padding-top:0px !important;width:90%"> |
| − | + | <div class="col-md-12 text-center"> | |
| − | + | <video autoplay controls loop style="width:85%;height:85%"> | |
| − | + | <source src="https://static.igem.org/mediawiki/2017/8/88/Final_vid.mp4" type="video/mp4"> | |
| − | + | </video> | |
| − | < | + | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
</div> | </div> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
</div> | </div> | ||
</div> | </div> | ||
| − | < | + | <section class="price-table"> |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
<div class="container section-wrapper"> | <div class="container section-wrapper"> | ||
| − | < | + | <div class="row" style="margin-bottom: 50px;"> |
| − | + | <div class="col-md-6 text-center" style="float: none;height: auto ; width: 90%; margin: auto; background-color: rgba(0, 0, 0, 0.4);"> | |
| − | + | <p><img style="float: right;" src="https://static.igem.org/mediawiki/2017/d/d4/CRISPR_PNG.png" alt="" width="679" height="988" /></p> | |
| − | + | <h3 dir="ltr" style="text-align: left;"><span style="font-size: 20pt; color: #ffffff;">Competing endogenous RNA network : Potential entrants to gene editing in Hepatocellular Carcinoma</span><br /><br /><br /> | |
| − | + | <h3 class="text-center" style="text-align: center;"><br /><br /><span style="font-size: 14pt; color: #ffffff;">Abstract</span></h3> | |
| − | Hepatocellular Carcinoma (HCC) is the leading cause of cancer deaths worldwide & ranked first among cancers | + | <p style="text-align: left;"><span style="font-size: 14pt; color: #ffffff;"> </span></p> |
| − | in males and next to breast cancer among females in | + | <span style="font-size: 14pt; color: #ffffff;">Hepatocellular Carcinoma (HCC) is the leading cause of cancer deaths worldwide & ranked first among cancers in males and next to breast cancer among females in</span><span style="font-size: 14pt; color: #ffffff;"> Egypt based upon results of National Cancer Registry Program of Egypt. "Grabbing the problem from the roots" is the best way to decently describe the use of CRISPR, a special gene editing technique that we will be using to modulate a certain circRNA and adjust its gene expression, which is down-regulated in hepatocellular carcinoma. This in consequence modifies miRNA expression thus amending the mRNA gene expression; which is the visible problem in our trials. This will lead us to adopt a novel strategy for miRNA suppression by using circRNAs. This is accomplished by utilizing a synthetic circuit to give rise to a springboard in our battle against cancer.</span><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /></h3> |
| − | + | </div> | |
| − | + | </div> | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | </div> | + | |
</div> | </div> | ||
| − | + | </section> | |
| − | + | <div class="twitter-feed purple" style="margin-bottom:50vh;background-color: rgba(0, 0, 0, 0.4);"> | |
| − | + | ||
<div class="container section-wrapper"> | <div class="container section-wrapper"> | ||
| − | + | <div class='col-md-3'></div> | |
| − | + | <div class='col-md-6 text-center'> | |
| − | + | <h2 class='text-center' style='margin-bottom:30px'> | |
| − | + | AFCM-Egypt</h2> | |
| − | + | <h3 class='text-center'> | |
| − | + | A Culture of Discipline and Innovation</h3> | |
| − | + | <a href="http://www.afcm.ac.eg/" class="btn btn-primary btn-outline with-arrow" target="_blank"> click here <i class="fa fa-arrow-right"></i></a></div> | |
| − | + | <div class='col-md-3'><img src="https://static.igem.org/mediawiki/2017/7/7b/AFCM_LOGO_PNG.png" alt="logo" style='width: 50%;float: right'></div> | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
</div> | </div> | ||
| − | |||
</div> | </div> | ||
| − | |||
<section class="section-wrapper add container" style="background-color:#808387;width:100%"> | <section class="section-wrapper add container" style="background-color:#808387;width:100%"> | ||
| − | <div class="slider-wrapper theme-mi-slider"> | + | <div class="slider-wrapper theme-mi-slider"> |
| − | <h3 class='text-center'>OUR SPONSORS</h3> | + | <h3 class='text-center'>OUR SPONSORS</h3> |
| − | <div class="afcmslider-holder"> | + | <div class="afcmslider-holder"> |
| − | + | <button class="afcmcontrols" id="afcmcontrols-left">❮</button> | |
| − | + | <button class="afcmcontrols" id="afcmcontrols-right">❯</button> | |
| − | + | <ul id="afcmslides"> | |
| − | + | <li class="afcmslide afcmshowing"> | |
| − | + | <img src="https://static.igem.org/mediawiki/2017/f/f1/1-AFCM-Egypt-sponsers-vitabiotics.png" style="width: 182px;padding-right: 20px;"> | |
| − | + | <img src="https://static.igem.org/mediawiki/2017/b/bd/3-AFCM-Egypt-sponsers-Pharco_Logo.png" style="width: 180px;padding-right: 18px;"> | |
| − | + | </li> | |
| − | + | <li class="afcmslide"> | |
| − | <img src="https://static.igem.org/mediawiki/2017/6/67/7-AFCM-Egypt-sponsers-Image-2.jpeg" style="width: 160px;padding-right: 15px;"> | + | <img src="https://static.igem.org/mediawiki/2017/3/3b/4-AFCM-Egypt-sponsers-Nationel_Research.png" style="width: 150px;padding-right: 15px;"> |
| − | + | <img src="https://static.igem.org/mediawiki/2017/6/67/7-AFCM-Egypt-sponsers-Image-2.jpeg" style="width: 160px;padding-right: 15px;"> | |
| − | + | <img src="https://static.igem.org/mediawiki/2017/e/eb/6-AFCM-Egypt-sponsers-SimEra.png" style="width: 150px;padding-right: 15px;"> | |
| − | + | <img src="https://static.igem.org/mediawiki/2017/3/37/5-AFCM-Egypt-sponsers-IDT.png" style="width: 150px;padding-right: 15px;"> | |
| − | + | <img src="https://static.igem.org/mediawiki/2017/6/60/9-AFCM-Egypt-sponsers-Benchling.png" style="width: 150px;padding-right: 15px;"> | |
| − | + | <img src="https://static.igem.org/mediawiki/2017/b/b4/8-AFCM-Egypt-sponsers-Zewail_logo.png" style="width: 150px;padding-right: 15px;"> | |
| − | + | </li> | |
| − | + | </ul> | |
| − | + | </div> | |
| − | + | </div> | |
| − | + | </section> | |
| − | + | <button id="myBtn" title="Go to top"><i class="fa fa-arrow-up fa-3x"></i></button> | |
| − | + | ||
| − | </section> | + | <script> |
| − | < | + | |
| − | <script> | + | |
$(document).ready(function() { | $(document).ready(function() { | ||
| + | $('#myBtn').click(function(){ | ||
| + | document.body.scrollTop = 0; | ||
| + | document.documentElement.scrollTop = 0; | ||
| + | }) | ||
| + | window.onscroll = function () { scrollFunction() }; | ||
| + | function scrollFunction() { | ||
| + | if (document.body.scrollTop > 20 || document.documentElement.scrollTop > 20) { | ||
| + | document.getElementById("myBtn").style.display = "block"; | ||
| + | } else { | ||
| + | document.getElementById("myBtn").style.display = "none"; | ||
| + | } | ||
| + | } | ||
| + | |||
| + | document.getElementById('navbar-toggle').onclick = function () { | ||
| + | var active = document.querySelector(".navbar-collapse"); | ||
| + | active.classList.toggle("in"); | ||
| + | } | ||
var slides = document.querySelectorAll('#afcmslides .afcmslide'); | var slides = document.querySelectorAll('#afcmslides .afcmslide'); | ||
var currentSlide = 0; | var currentSlide = 0; | ||
| − | + | var slideInterval ; | |
var controls = document.querySelectorAll('.afcmcontrols'); | var controls = document.querySelectorAll('.afcmcontrols'); | ||
| − | + | ||
var next = document.getElementById('afcmcontrols-left'); | var next = document.getElementById('afcmcontrols-left'); | ||
var previous = document.getElementById('afcmcontrols-right'); | var previous = document.getElementById('afcmcontrols-right'); | ||
| Line 304: | Line 294: | ||
pauseSlideshow(); | pauseSlideshow(); | ||
}; | }; | ||
| + | |||
| + | |||
}); | }); | ||
| − | </script> | + | </script> |
</body> | </body> | ||
</html> | </html> | ||
{{Template:AFCM-Egypt/footer}} | {{Template:AFCM-Egypt/footer}} | ||
Latest revision as of 20:11, 31 October 2017
Competing endogenous RNA network : Potential entrants to gene editing in Hepatocellular Carcinoma
Abstract
Abstract
Hepatocellular Carcinoma (HCC) is the leading cause of cancer deaths worldwide & ranked first among cancers in males and next to breast cancer among females in Egypt based upon results of National Cancer Registry Program of Egypt. "Grabbing the problem from the roots" is the best way to decently describe the use of CRISPR, a special gene editing technique that we will be using to modulate a certain circRNA and adjust its gene expression, which is down-regulated in hepatocellular carcinoma. This in consequence modifies miRNA expression thus amending the mRNA gene expression; which is the visible problem in our trials. This will lead us to adopt a novel strategy for miRNA suppression by using circRNAs. This is accomplished by utilizing a synthetic circuit to give rise to a springboard in our battle against cancer.
